{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:06:24Z","timestamp":1791576384549,"version":"4.3.4"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Neuroblastoma is a biologically and clinically heterogeneous disease. Based on recent studies demonstrating an association between the primary tumor site, prognosis, and commonly measured tumor biological features, we hypothesized that neuroblastomas arising in different sites would show distinct genomic features reflective of the developmental biology of the sympathicoadrenal nervous system.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We first compared genomic and epigenomic data of primary diagnostic neuroblastomas originating in the adrenal gland (n\u2009=\u2009646) compared to thoracic sympathetic ganglia (n\u2009=\u2009118). We also evaluated association of common germline variation with these primary sites in 1027 European-American neuroblastoma patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We observed higher rates of MYCN amplification, chromosome 1q gain, and chromosome 11q deletion among adrenal tumors, which were highly predictive of functional RNA signatures. Surprisingly, thoracic neuroblastomas were more likely to harbor ALK driver mutations than adrenal cases among all cases (odds ratio\u2009=\u20091.89, 95% confidence interval\u2009=\u20091.04 to 3.43), and among cases without MYCN amplification (odds ratio\u2009=\u20092.86, 95% confidence interval\u2009=\u20091.48 to 5.49). Common germline single nucleotide polymorphisms (SNPs) in BARD1 (previously associated with high-risk neuroblastoma) were found to be strongly associated with predisposition for origin at adrenal, rather than thoracic, sites.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Neuroblastomas arising in the adrenal gland are more likely to harbor structural DNA aberrations including MYCN amplification, whereas thoracic tumors show defects in mitotic checkpoints resulting in hyperdiploidy. Despite the general association of ALK mutations with high-risk disease, thoracic tumors are more likely to harbor gain-of-function ALK aberrations. Site of origin is likely reflective of stage of sympathetic nervous system development when malignant transformation occurs and is a surrogate for underlying tumor biology.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jnci\/djz027","type":"journal-article","created":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T23:15:57Z","timestamp":1550618157000},"page":"1192-1201","source":"Crossref","is-referenced-by-count":34,"title":["Differences in Genomic Profiles and Outcomes Between Thoracic and Adrenal Neuroblastoma"],"prefix":"10.1093","volume":"111","author":[{"given":"Derek A","family":"Oldridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Russ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G","family":"DuBois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zalman","family":"Vaksman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael P","family":"Mosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon J","family":"Diskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M","family":"Maris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine K","family":"Matthay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,21]]},"reference":[{"issue":"1","key":"2019111419011507600_djz027-B1","first-page":"93","article-title":"An open letter to the Director General of the Cancer Research Campaign","volume":"33","author":"Goodman","year":"1999","journal-title":"J R Coll Physicians Lond"},{"issue":"15","key":"2019111419011507600_djz027-B2","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1200\/JCO.2009.27.0421","article-title":"Outcomes for children and adolescents with cancer: challenges for the twenty-first century","volume":"28","author":"Smith","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111419011507600_djz027-B3","author":"Matthay"},{"issue":"28","key":"2019111419011507600_djz027-B4","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1200\/JCO.2014.56.1621","article-title":"Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project","volume":"32","author":"Vo","year":"2014","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111419011507600_djz027-B5","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.1993.11.8.1466","article-title":"Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment","volume":"11","author":"Brodeur","year":"1993","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111419011507600_djz027-B6","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/pbc.24433","article-title":"Children's Oncology Group's 2013 blueprint for research: neuroblastoma","volume":"60","author":"Park","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2019111419011507600_djz027-B7","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1038\/bjc.2012.375","article-title":"Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project","volume":"107","author":"Schleiermacher","year":"2012","journal-title":"Br J Cancer"},{"issue":"6","key":"2019111419011507600_djz027-B8","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/cncr.29848","article-title":"Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: a report from the International Neuroblastoma Risk Group project","volume":"122","author":"Thompson","year":"2016","journal-title":"Cancer"},{"issue":"21","key":"2019111419011507600_djz027-B9","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1002\/cncr.30873","article-title":"Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: a report from the Children's Oncology Group","volume":"123","author":"Campbell","year":"2017","journal-title":"Cancer"},{"issue":"7215","key":"2019111419011507600_djz027-B10","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/nature07261","article-title":"Identification of ALK as a major familial neuroblastoma predisposition gene","volume":"455","author":"Mosse","year":"2008","journal-title":"Nature"},{"issue":"7215","key":"2019111419011507600_djz027-B11","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature07398","article-title":"Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma","volume":"455","author":"Janoueix-Lerosey","year":"2008","journal-title":"Nature"},{"issue":"7215","key":"2019111419011507600_djz027-B12","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nature07399","article-title":"Oncogenic mutations of ALK kinase in neuroblastoma","volume":"455","author":"Chen","year":"2008","journal-title":"Nature"},{"issue":"7215","key":"2019111419011507600_djz027-B13","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nature07397","article-title":"Activating mutations in ALK provide a therapeutic target in neuroblastoma","volume":"455","author":"George","year":"2008","journal-title":"Nature"},{"issue":"6","key":"2019111419011507600_djz027-B14","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/ng.374","article-title":"Common variations in BARD1 influence susceptibility to high-risk neuroblastoma","volume":"41","author":"Capasso","year":"2009","journal-title":"Nat Genet"},{"issue":"11","key":"2019111419011507600_djz027-B15","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1002\/ijc.31822","article-title":"Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor-suppressor","volume":"143","author":"Cimmino","year":"2018","journal-title":"Int J Cancer"},{"issue":"10","key":"2019111419011507600_djz027-B16","doi-asserted-by":"crossref","first-page":"A014415.","DOI":"10.1101\/cshperspect.a014415","article-title":"Neuroblastoma and MYCN","volume":"3","author":"Huang","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"2019111419011507600_djz027-B17","doi-asserted-by":"crossref","first-page":"6416","DOI":"10.18632\/oncotarget.23740","article-title":"MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group","volume":"9","author":"Niemas-Teshiba","year":"2018","journal-title":"Oncotarget"},{"issue":"21","key":"2019111419011507600_djz027-B18","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1056\/NEJMoa052399","article-title":"Chromosome 1p and 11q deletions and outcome in neuroblastoma","volume":"353","author":"Attiyeh","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111419011507600_djz027-B19","doi-asserted-by":"crossref","first-page":"114.","DOI":"10.1186\/s12943-017-0686-8","article-title":"11q deletion in neuroblastoma: a review of biological and clinical implications","volume":"16","author":"Mlakar","year":"2017","journal-title":"Mol Cancer"},{"issue":"3","key":"2019111419011507600_djz027-B20","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ccr.2012.02.010","article-title":"Activated ALK collaborates with MYCN in neuroblastoma pathogenesis","volume":"21","author":"Zhu","year":"2012","journal-title":"Cancer Cell"},{"issue":"12","key":"2019111419011507600_djz027-B21","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.18632\/oncotarget.2036","article-title":"Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells","volume":"5","author":"Montavon","year":"2014","journal-title":"Oncotarget"},{"issue":"141","key":"2019111419011507600_djz027-B22","doi-asserted-by":"crossref","first-page":"141ra91.","DOI":"10.1126\/scitranslmed.3003967","article-title":"Targeted expression of mutated ALK induces neuroblastoma in transgenic mice","volume":"4","author":"Heukamp","year":"2012","journal-title":"Sci Transl Med"},{"issue":"5","key":"2019111419011507600_djz027-B23","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ccell.2014.09.019","article-title":"ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma","volume":"26","author":"Bresler","year":"2014","journal-title":"Cancer Cell"},{"issue":"10","key":"2019111419011507600_djz027-B24","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx093","article-title":"Evaluation of genetic predisposition for MYCN-amplified neuroblastoma","volume":"109","author":"Hungate","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2019111419011507600_djz027-B25","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.canlet.2015.11.017","article-title":"More than the genes, the tumor microenvironment in neuroblastoma","volume":"380","author":"Borriello","year":"2016","journal-title":"Cancer Lett"},{"issue":"3","key":"2019111419011507600_djz027-B26","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ccell.2017.08.002","article-title":"LMO1 synergizes with MYCN to promote neuroblastoma initiation and metastasis","volume":"32","author":"Zhu","year":"2017","journal-title":"Cancer Cell"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/111\/11\/1192\/30490922\/djz027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/111\/11\/1192\/30490922\/djz027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T19:02:01Z","timestamp":1573758121000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/111\/11\/1192\/5355061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,21]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,2,21]]},"published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djz027","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11]]},"published":{"date-parts":[[2019,2,21]]}}}